Intravesical Therapy of Low Stage Bladder Carcinoma with Mitomycin C: Comparison of Results in Untreated and Previously Treated Patients

Prout, George R.; Griffin, Pamela P.; Nocks, Barry N.; DeFuria, M. D.; Daly, James J.

doi:10.1016/s0022-5347(17)54246-9

Cited by 37 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nissenkorn et al (4) apparently thought that the reaction was caused by contact of the hands with MMC-containing urine, because they suggested that "careful cleansing of the hands and perineum on the day of treatment can prevent most skin reactions" (4). This concept has been maintained throughout the urological literature (18,19,21,(45)(46)(47), although some authors (20,21,29) suggested that systemic absorption may sometimes play a role.…”

Section: Discussionmentioning

confidence: 99%

Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C

Groot¹,

Conemans²

1991

Contact Dermatitis

View full text Add to dashboard Cite

6 cases of contact allergy to the antitumor antibiotic mitomycin C from intravesical instillation are described. Reports suggest that up to 9% of patients treated with mitomycin C for chemoresection/prevention of superficial bladder cancer will develop cutaneous side-effects. Patients may present either with vesicular dermatitis of the hands and feet and/or dermatitis of the genitals, or with more widespread eruptions. Probably most, if not all, skin reactions are caused by contact allergy. The distribution is suggestive of systemic contact dermatitis from mitomycin C absorbed from the vesical mucosa.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C

Groot¹,

Conemans²

1991

Contact Dermatitis

View full text Add to dashboard Cite

show abstract

“…Several following studies in the early eighties supported the preliminary results (12, 13) on the efficacy MMC intravesical instillation, confirming both its ablative and prophylactic efficacy (24)(25)(26)(27)(28). Issell et al (29) in 1984 reported a partial or complete objective response rate of 68% and 42%, respectively, out of 60 patients affected by NMIBC not responsive to thio-tepa, including 50% of patients with Grade 3 and 70% of patients with T1 tumors.…”

Section: Youthmentioning

confidence: 73%

Mitomycin C from Birth to Adulthood

et al. 2016

View full text Add to dashboard Cite

Mitomycin C (MMC) intravesical therapy for "superficial" papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks. In the following decades, many large randomized studies showed the benefit of intravesical prophylaxis with MMC versus transurethral resection (TUR) alone. Since 2002, the role of adjuvant intravesical chemotherapy and of an early MMC instillation in preventing recurrence compared with TUR alone has been confirmed by large meta-analyses and stated by the European Association of Urology (EAU) guidelines. The need for further intravesical chemotherapy after the early instillation in patients at intermediate-high risk of recurrence has been proved by several trials. Although intravesical Bacillus Calmette-Guerìn (BCG) is considered the best choice for high-risk patients and MMC for the low-risk group, both MMC and BCG can be given to prevent recurrence in intermediate-risk patients. However, the higher efficacy of BCG over MMC is evident only if maintenance regimen is administered. Despite its proven efficacy, immediate intravesical MMC is not yet fully entered in common clinical practice and efforts should be made by the urologists to optimize its adoption.

show abstract

“…Our observations confirmed the experience of others with Mitomycin C Bracken, 1982;Mishina et al, 1982;Prout et al, 1982), namely that small but not large papillary tumours respond well regardless of number. The objective and symptomatic response of carcinoma in situ is a striking feature of this study.…”

Section: Discussionmentioning

confidence: 91%

“…Japanese experience with the drug has been reviewed by Mishina et al (1982). Subsequent studies have suggested that it is a most promising drug which s e e m to be as effective as any other agent in clinical use and which exhibits minimal systemic and local toxicity Bracken, 19821;Prout et al, 1982).…”

mentioning

confidence: 96%

A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder Cancer

Harrison¹,

Green²,

Newling³

et al. 1983

British Journal of Urology

View full text Add to dashboard Cite

Twenty-three patients with histologically proven superficial bladder cancer (Tis, Ta, T1) were treated with intravesical instillations of Mitomycin C at a dose of 20 mg in 20 ml of water 3 times weekly for 21 instillations. Seventeen patients (77%) showed complete disappearance of all known disease and a further 4 showed partial responses. In 8 patients toxic effects developed (thrombocytopaenia 1, chemical cystitis 2, skin rash 3, urinary tract infection 2). All resolved rapidly on stopping the treatment but were severe enough in 5 patients to prevent them from receiving a full course of treatment.

show abstract

Intravesical Therapy of Low Stage Bladder Carcinoma with Mitomycin C: Comparison of Results in Untreated and Previously Treated Patients

Cited by 37 publications

References 10 publications

Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C

Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C

Mitomycin C from Birth to Adulthood

A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder Cancer

Contact Info

Product

Resources

About